Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli l-asparaginase in the treatment of patients with acute lymphoblastic leukemia: Results from Children's Oncology Group Study AALL07P4

Authors

Anne Angiolillo, George Washington UniversityFollow
Reuven J. Schore, George Washington UniversityFollow
Meenakshi Devidas
Michael J. Borowitz
Andrew J. Carroll
Ashley R. Lane, George Washington University
Gregory H. Reaman, George Washington UniversityFollow
+12 additional authors

Document Type

Journal Article

Publication Date

12-2014

Journal

Journal of Clinical Oncology

Volume

Volume 32, Issue 34

Inclusive Pages

3874-3892

Keywords

Antineoplastic Agents--pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols--pharmacokinetics; Asaparaginase--pharmacokinetics; Polyethylene Glycols--pharmacokinetics; Precursor Cell Lymphoblastic Leukeumia-Lymphoma--drug therapy

Comments

PMCID: PMC4239306 [Available on 2015-12-01]

APA Citation

Angiolillo, A.L., Schore, R.J., Devidas, M., Borowitz, M.J., Carroll, A.J. et al. (2014). Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. Journal of Clinical Oncology, 32(34), 3874-3882.

Peer Reviewed

1